Cargando…

Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study

Nivolumab has shown durable response and safety in patients with hepatocellular carcinoma (HCC) in previous trials. However, real-world data of nivolumab in HCC patients, especially those with Child–Pugh class B, are limited. To investigate the effectiveness and safety of nivolumab in a real-world c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Won-Mook, Lee, Danbi, Shim, Ju Hyun, Kim, Kang Mo, Lim, Young-Suk, Lee, Han Chu, Yoo, Changhoon, Park, Sook Ryun, Ryu, Min-Hee, Ryoo, Baek-Yeol, Choi, Jonggi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409289/ https://www.ncbi.nlm.nih.gov/pubmed/32698355 http://dx.doi.org/10.3390/cancers12071968

Ejemplares similares

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
por: Jin, Sujin, et al.
Publicado: (2023)

Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosis
por: Chapin, William J., et al.
Publicado: (2022)

Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study
por: Jeon, Dongsub, et al.
Publicado: (2023)

The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas
por: Choi, Tae Won, et al.
Publicado: (2015)

Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma
por: Son, Seok Hyun, et al.
Publicado: (2014)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2019)

Efficacy of Liver Resection for Single Large Hepatocellular Carcinoma in Child-Pugh A Cirrhosis: Analysis of a Nationwide Cancer Registry Database
por: Hong, Suk Kyun, et al.
Publicado: (2021)

Development of machine learning-based clinical decision support system for hepatocellular carcinoma
por: Choi, Gwang Hyeon, et al.
Publicado: (2020)

Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
por: Itoh, Shinji, et al.
Publicado: (2022)

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
por: Liu, Chen-Hua, et al.
Publicado: (2021)

Alteration of prognostic efficacy of albumin‐bilirubin grade and Child‐Pugh score according to liver fibrosis in hepatocellular carcinoma patients with Child‐Pugh A following hepatectomy
por: Miyata, Tatsunori, et al.
Publicado: (2021)

The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment
por: Choi, Jonggi, et al.
Publicado: (2022)

Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy
por: Hasan, Shaakir, et al.
Publicado: (2017)

Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma with Child-Pugh B7
por: Jiang, Jian-Qiang, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
por: Cheon, Jaekyung, et al.
Publicado: (2023)

Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B
por: Choi, Won-Mook, et al.
Publicado: (2022)

A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
por: Park, Sook Ryun, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients With Child-Pugh B or C Cirrhosis
por: Lee, Peter, et al.
Publicado: (2020)

Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013)

Changes in Inflammatory Markers Predict the Prognosis of Resected Hepatocellular Carcinoma with Child–Pugh A
por: Zhou, Jing, et al.
Publicado: (2022)

Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma
por: Costa, Frederico, et al.
Publicado: (2023)

Clinical impact of carbon‐ion radiotherapy on hepatocellular carcinoma with Child‐Pugh B cirrhosis
por: Hiroshima, Yuichi, et al.
Publicado: (2023)

Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma
por: Suh, Young Ju, et al.
Publicado: (2021)

Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours
por: Kim, Yong-il, et al.
Publicado: (2020)

Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05)
por: Bae, Sun Hyun, et al.
Publicado: (2019)

A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child–Pugh Scores of 5 or 6
por: Hung, Hung-Hsu, et al.
Publicado: (2014)

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
por: FEDERICO, ALESSANDRO, et al.
Publicado: (2015)

Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child–Pugh B cirrhosis
por: Terashima, Takeshi, et al.
Publicado: (2016)

Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function
por: Huynh, Jasmine, et al.
Publicado: (2022)

Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
por: Lee, Sumin, et al.
Publicado: (2022)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Child Pugh and ALBI grade: past, present or future?
por: Rimini, Margherita, et al.
Publicado: (2020)

Genetic-based Risk Assessment for Hepatocellular Carcinoma in Patients with Hepatitis C: Where Do We Stand?
por: Choi, Jonggi, et al.
Publicado: (2016)

Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis
por: Yoo, Changhoon, et al.
Publicado: (2016)

Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
por: Lee, Jungnam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cqac8d8d1b2mfc1dtm6u7t9occ